c-Myc

Myc



c-Myc is the master transcription factor for cell proliferation and is involved in numeroushematological and solidcancers.

Proto-oncogene c-Myc, encoding one of the most important transcription factors, plays a pivotal role in tumor initiation and progression. c-Myc regulates hundreds of disparate target genes that participate numerous biological effects, such as cell proliferation, apoptosis, differentiation, and stem cell self-renewal. c-Myc is one of the four factors used in reprogramming somatic cells to induce pluripotent stem (iPS) cells and is implicated in maintaining cancer stem-like cells (CSCs).

The transcription factor c-Myc is a key mediator of the Notch signaling–regulated T cell differentiation. In a well-established in vitro differentiation model of T lymphocytes from hematopoietic stem cells, Notch1 and 4 directly promotes c-Myc expression; dominant-negative (DN) c-Myc inhibits early T cell differentiation. Moreover, the c-Myc expression activated by Notch signaling increases the expression of survivin, an inhibitor of apoptosis (IAP) protein.

c-Myc gene, as a transcription factor of hTERT, is over expressed in a variety of tumors.c-Myc and hTERT expression in local recurrent gastric cancer tissues is much higher than in primary gastric cancer tissues at the protein and mRNA levels.

c-Myc Inhibitors & Modulators

10058-F4

Cat. No.: HY-12702

Bioactivity: 10058-F4 is a **c-Myc** inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.

Purity: 99.92%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



10074-G5

Cat. No.: HY-100996

Bioactivity: 10074-G5 is an inhibitor of **c-Myc-Max** dimerization with an **IC_{50}** of 146 μM.

Purity: 97.07%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



IZCZ-3

Cat. No.: HY-111411

Bioactivity: IZCZ-3 is a potent **c-MYC transcription** inhibitor with antitumor activity [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 100 mg, 250 mg



KJ Pyr 9

Cat. No.: HY-19735

Bioactivity: KJ Pyr 9 is an inhibitor of **MYC** with a **K_d** of 6.5 nM in in vitro assay.

Purity: 99.25%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



KSI-3716

Cat. No.: HY-12703

Bioactivity: KSI-3716 is a **c-Myc** inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



ML327

Cat. No.: HY-103038

Bioactivity: ML327 is a blocker of **MYC** which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).

Purity: 98.04%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Mycro 3

Cat. No.: HY-100669

Bioactivity: Mycro 3 is potent and selective for **c-Myc** in whole cell assays.

Purity: 98.63%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg